In the usual management of hypertension, for example, many patients drop out of care entirely, and of those who continue to attend appointments, only about half to two-thirds will take enough medication to achieve systematic blood pressure reductions. 1 LOW compliance can oe increasea oy a numoer oi techniques.* Unfortunately, to apply complianceimproving interventions efficiently, one has to identify the patient with low compliance. In research settings, extravagant efforts to measure compliance objectively can be undertaken such as unobtrusive pill counts on unannounced home visits'-4 or assessment of drug levels in the patient's biologic fluids. However, these techniques are not usually feasible, available or affordable in the routine clinical care of patients.
Moreover, it has been shown repeatedly that clinicians' personal assessments of their patients' compliance are thoroughly unreliable.*"* A recent study of compliance-improving maneuvers among newly treated hypertensive steelworkers provided us with an opportunity to compare the accuracy of several easily available clinical assessments of compliance with a more rigorous, quantitative, objective assessment.
Subjects and Methods
The patients in this investigation were participants in a series of randomized trials of strategies to improve compliance with antihypertensive therapy that have been described in detail elsewhere.*-* In brief, a random two-thirds (5400) of the male employees of the Dominion Foundries and Steel Limited of Hamilton, Canada, were screened for hypertension. Of those invited to screening, 5.1% refused either the first or second blood pressure assessment. A total of 245 men met the following criteria: average fifth phase diastolic blood pressure > 95 mm Hg (average of second and third of three readings taken with the patient sitting quietly on each of two separate occasions over a 3-month period); no antihypertensive therapy for at least 6 months prior to screening; no daily medications; and no remediable secondary form of hypertension. After explanation of the study, 230 (94%) of these men consented to participate. All 230 were successfully referred to their family physicians or a plant physician for further assessment and care. All 83 physicians to whom patients had been referred agreed to cooperate with the study. Therapeutic decisions were left entirely up to these physicians and they elected to treat 145 patients with antihypertensive medications, leaving the remaining 85 patients untreated or on tranquilizers or nonpharmacologic treatments such as weight loss or sodium restriction. Of the 145 men placed on antihypertensive drugs, five (3%) were taken off medication before 6 months, six (4%) were lost to follow-up, and 134 (96% of those on treatment at 6 months) were assessed for compliance.
The following techniques were utilized to assess compliance.
Pill Counts
Before entry, each participant consented to be visited at home during the course of the study. Patients were first visited 6 months following entry. Arrangements to visit, for the ostensible purpose of assessing blood pressure "at home," were made by telephone, usually on the same day that the visit took place. At the visit, the blood pressure was recorded and the patient was asked to present all medications in order to bring the visitor "up to date" on the patient's current prescription. The patient was then asked to provide a urine specimen and the tablets were counted during his absence. The prescribed regimen, dispensing pharmacy, and dispensing date were recorded, and the pharmacy was contacted after the visit to determine the number of tablets dispensed if this information was not available on the pill bottle label. At the end of the visit the patient was asked if he kept any of his medication elsewhere and if so how much was there. He was also asked whether he began taking pills from the container on hand on the dispensing date or, if not, when he had started the medication. If the prescription dispensing date was less than 1 month prior to the time of the home visit, information on the previous prescription was sought from the patient and/or pharmacy to extend the period of compliance assessment for at least 1 month. Compliance was calculated by dividing the number of pills missing from all containers by the number of pills which should have been missing if the patient had taken all his medicine as prescribed.
Serum Uric Acid and Potassium Determinations
To assess whether compliance could be assessed from the changes in serum uric acid and potassium levels produced by diuretics (used by 80% of patients in this study) we measured these substances through routine community laboratory services at entry and 3 and 6 months after the start of therapy.
Urinary Chlorthalidone and Hydrochlorothiazide
Urine specimens were collected at the 6-month home visit and again at the 6-month worksite assessment to be analyzed for chlorthalidone and hydrochlorothiazide by thin-layer chromatography. The purpose of the home specimen was to ascertain its correlation with the pill count obtained at that time. The urinary assessment at a scheduled visit at work was performed to determine if it was as reliable an indicator of compliance as the urine findings at the home visit. The presence of drug in a specimen was rated on a 5-point semiquantitative scale, with 0 for absent through 4+ for high concentration.
Interview
At 6 months after entry, patients were questioned by trained interviewers at the time of the home visit. Assessment of compliance was introduced in the following fashion: "People often have difficulty taking their pills for one reason or another and we are interested in finding out any problems that occur so that we can understand them better." Patients were then asked whether they ever missed their pills and, if so, to state their current prescriptions and the average number of tablets missed per day, week, and month.
Patients were also questioned concerning their "health beliefs'" 110 at entry and 6 months following entry. Questions concerned the patient's perceptions of personal susceptibility to developing hypertension, the seriousness of hypertension, the benefits of therapy, attitudes toward drug-taking and barriers to compliance, and the dependency implications of illness.
In addition, data were collected concerning patients' sociodemographic features, past health, and current and past physical and psychological complaints, with special emphasis on possible target organ damage and drug side effects.
Response to Therapy
Blood pressures were recorded at the worksite medical center at entry and 6 months following entry by observers who were unaware of the patient's treatment status. Using standard mercury sphygmomanometers, blood pressures were taken as the average of the second and third of three readings in the right arm with the patient in the sitting position after quiet rest for at least 5 minutes.
Results

Entry Characteristics
Selected entry characteristics of the 134 participants who were available for compliance assessments at 6 months are recorded in table 1. By study design, all subjects were male; most were middle-aged, married laborers. A wide range of ethnic backgrounds was represented, with the majority of the participants being of English, Italian, or SerbCroatian origin. The mean entry blood pressure of participants who were treated after referral was 155/104 mm Hg and this was significantly higher by guest on April 6, 2017 http://hyper.ahajournals.org/ Downloaded from (p < 0.05) than the mean entry blood pressure of those left untreated. Of the treated participants, 39% had been aware of their hypertension prior to study entry. By study entry criteria, no subjects were on treatment for their hypertension at the time of entry but 6% had been on therapy at some time in the past.
Compliance Assessment: Pill Counts Pill counts were obtained at home for 134 men who were on antihypertensive therapy 6 months following entry to the project. Five men expressed initial reluctance to the home visit but none refused. The only recurring difficulty encountered was distinguishing the exact date that a new bottle of tablets was actually begun from the date that the tablets were dispensed from the pharmacy: a few patients on repeat prescriptions could only provide approximate dates. In most cases, the starting date could be identified within a range of 1 or 2 days. It was possible to determine compliance for all patients over the interval of at least 1 month prior to the 6-month assessment.
The frequency distribution of compliance rates is shown in figure 1 . Prior to the study a level of "at least 80% of medications consumed" was set as the standard for rating a patient as "compliant." It can be seen that 56% of patients met this standard.
Because the pill count method was objective, quantitative, and available on all subjects, it was used as the standard of comparison for the assessment methods below.
Serum Potassium and Uric Acid
Serum potassium and uric acid levels are compared with pill count compliance in tables 2 and 3. It can be seen that the level of potassium at 3 months does correlate in a statistically significant fashion with pill count compliance at 6 months but by 6 months this correlation has disappeared. The serum uric acid level does not significantly correlate with compliance at either time. On the other hand, the change in blood levels from pretreatment to posttreatment periods provides a better correlation with compliance for both potassium and uric acid at 3 months and, for uric acid only, at 6 months.
Although most patients were prescribed a thiazide diuretic or chlorthalidone for their hypertension, this was not true for 20% of the patients. In addition, for many of the patients on these diuretics the biochemical effect was masked or diminished by cotreatment with a potassium-sparing agent, potassiumsupplementation or allopurinol. Table 3 reveals the effects of limiting the analysis to patients for whom potassium-supplementing or potassium-sparing drugs or allopurinol were not prescribed. The correlations are all statistically .significant and do rise as the obscuring influences are removed. Obviously, however, the relevance of the determinations to all hypertensive patients decreases as the tests become more selectively applied. Furthermore, even under the most ideal circumstances the correlations are imperfect being -.54 for potassium and .36 for uric acid. Surprisingly, correlations between potassium and uric acid changes from entry to 6 months and compliance at 6 months were all lower than the correlations of changes from entry to 3 months with 6 month compliance.
To assess the predictive value of changes in serum potassium and uric acid for clinical decision-making, the changes in these determinations over the first 3 months of therapy were dichotomized into high and low levels and then compared with 6-month pill count compliance, dichotomized at 80% as described above. Various cutpoints for change in the lab tests were explored and the ones shown in tables 4 and 5 represent the optimum for predicting compliance for the 99 patients on diuretics for whom both biochemical changes were available. For serum potassium, 21 of 31 patients with a reduction of less than 0.5 mEq// were noncompliant (negative predictive value of 66%) and a reduction of 0.5 mEq// or more carried a 66% chance of being compliant (positive predictive value). In other words, at this prevalence of compliance (about 65% of patients were compliant) two-thirds of patients were correctly labelled using the cutpoints above. Serum uric acid changes dichotomized as less than 1 mg% and at least 1 mg% produced almost identical results, as shown in table 5. au Urinary Chlorthalidone and Hydrochlorothiazide Urine specimens were obtained at the 6-month home visit from 71 (90%) of 79 men on chlorthalidone and at the 6-month worksite check from 63 (80%) of these men. The data presented in table 6 (A, B) provide the optimum accuracy of the urinary chlorthalidone test results, based on exploration of the four cutpoints for the five urine concentration categories. The accuracy of the test is similar at both home and the worksite and is somewhat better than assessment of serum uric acid and potassium. None of the patients at 0% compliance by pill count had chlorthalidone present in their urine. However, many patients with compliance below 80% still had detectable levels of chlorthalidone in their urine, limiting the usefulness of the test in detecting low compliers who are still taking some medication.
Only 26 men were prescribed hydrochlorothiazidecontaining medications. Urine specimens were ob- TABLB tained on 22 of these patients at home and 21 at the worksite. Comparisons with pill counts are provided in table 6 (C, D). The determinations have approximately the same value as those for potassium and uric acid but, of course, could only be applied to the small number of patients on hydrochlorothiazide in our study. Again, many of the patients with suboptimal compliance had hydrochlorothiazide in their urine, limiting the usefulness of the test in detecting low compliance.
Comparison of Compliance Status by Change in Serum Uric Acid (Entry to S Months) with PHI Count Compliance for Patients on Thiatides
Interriews
On direct questioning at the time of home assessment, 130 (97%) patients provided estimates of their own compliance. Self-reports of compliance correlated better with concurrent pill count compliance than any of the biochemical tests, giving a correlation coefficient of 0.74 (p < 0.0001). The best dichotomization of self-report compliance for clinical decisionmaking is provided in table 7. Seventy-five percent of the patients were correctly classified using self-reports and it can be seen that 90% of patients who admitted to taking less than 90% of their medications were found noncompliant by pill count. However, only half of the patients who stated they were compliant were found to be compliant on pill count and when the patient's quantitative estimates were compared with quantitative pill count rates even those who admitted to noncompliance tended to overestimate their compliance, the average overestimate being 17%, with a wide variance.
In addition to direct questions about compliance, patients were asked about their health beliefs. Table 8 provides the correlations between these beliefs and compliance. Patient's beliefs prior to starting therapy that the therapy for hypertension is safe and that illness does not imply a state of social dependency were significantly correlated with compliance at six months but the correlations were of low order (0.15 and 0.23 respectively). Reassessment of health beliefs at 6 months revealed significant correlations between compliance and beliefs in the seriousness of hypertension, the safety of drug therapy and that having hypertension does not imply a state of social dependency. However, the multiple correlation coefficient for all beliefs at 6 months was only 0.39, much less than that for simply asking the patient directly about his compliance. Furthermore, as is shown in the last column of this table, when the patient's self-report of compliance is taken into account, health beliefs provide no additional information. Fifty-two additional variables were tested for their correlation with compliance. These included demographic factors such as age, marital status, and ethnic origin; past and family history of chronic illness; prior use of and satisfaction with medical and dental services; symptomatic complaints on functional inquiry (including complaints commonly associated with ingestion of antihypertensive medication); and perception of overall health and physical capability. Of these variables, only the following six were significantly correlated with high compliance: older age; higher job category; having seen a physician in the 2 years prior to the study; reported capability of performing strenuous or moderate physical activity; perception that health had improved over the 6 months following entry to the project; satisfaction with prior medical care. However, given that 52 correlations were tested, one would expect a few findings beyond the 5% probability level on the basis of chance alone. If the probability required to achieve "statistical significance" is adjusted for the number of tests performed (11) none of the six findings above achieves statistical significance.
Response to Therapy
To the extent that antihypertensive therapy is efficacious and that sufficiently potent medication is prescribed, compliance should be correlated with blood pressure reduction. In fact, a statistically significant correlation was found between 6-month compliance and the reduction in diastolic blood pressure. However, this correlation was of low order (r = 0.17, p < 0.025). The clinical utility of using blood pressure control as a measure of compliance is shown in table 9. Of 64 patients with controlled blood pressures, 43 (67%) were compliant whereas 46% of those whose blood pressure remained elevated were compliant. While the difference is statistically significant (p < 0.025), many individuals (40%) were misclassified when blood pressure reduction was used as a measure of compliance.
Combinations of Tests
Various permutations and combinations of the tests above were compared with pill count compliance to determine if sensitivity, specificity and accuracy could be improved. One such combination is shown in table 8: knowledge of health beliefs did not improve the accuracy of interpreting the patient self-reports. Combinations for self-reports, biochemical determinations, and urinary drug levels also did not improve accuracy and, in some cases, produced worse results than those obtained by interview alone.
Discussion
The need for simple and accurate measures of patient compliance is obvious in the treatment of ambulatory patients with chronic conditions. For research purposes, awkward methods of compliance assessment can be applied such as pill counts. We believe that these can be accurate only if the patient is unaware of the purpose of the assessment. From practical experience it is difficult to induce patients to bring all of their medication with them to clinic visits and it is possible for patients to systematically alter the number of pills they present when they become aware that their pills are being counted. However, concealing the purpose of the assessment lacks candor and is difficult or impossible to maintain beyond one or two visits. In our investigation we believe pill counts provided an objective, accurate and quantitative measure of compliance because they were performed in the patients' homes without prior warning. However, because of the difficulties alluded to above and the expense of individual home visits we do not recommend pill counts for routine clinical use and merely offer them here as a standard by which simpler assessments can be judged.
Direct questioning of the patient correlated best with the pill count results in our study. Although patients tended to overestimate their compliance, three-quarters were correctly identified by this approach and 90% of patients who admitted noncompliance were verified as noncompliant, making it virtually unnecessary to perform additional assessments on those who state noncompliance. Indeed, other studies have produced similar results for different conditions."• 1S In addition, there is also some evidence that it is the noncompliant patients who state their noncompliance on direct questioning who are more likely to respond to interventions to promote compliance." Thus, asking the patient about his or her compliance would appear to be an easily obtained, universally applicable, quantitative and useful measure of medication compliance. On the other hand, asking additional questions about the patient's health beliefs, sociodemographic characteristics, past and family health and functional state did not augment the detection of low compliance in our investigation.
Serum urate and potassium and qualitative urinary chlorthalidone and hydrochlorothiazide assessments did not fare well by the standard of pill counts. At best only about two-thirds of patients are correctly identified by these techniques and even then the tests can only be applied to the subset of hypertensive patients who are on these medications.
Finally, the therapeutic response, while correlated with compliance, was not a good measure of the rate of compliance in our study. This may well be partly due to the lack of therapeutic vigor applied by the physicians who treated participants in the study: 78% of patients were placed on one medication alone and 43% did not achieve good blood pressure control despite high compliance. Nevertheless, it remains to be shown that blood pressure response is useful in assessing compliance even under optimal therapeutic conditions. From a very pragmatic viewpoint, however, it might be appropriate to restrict attempts to measure compliance to those patients for whom blood pressure remains high despite seemingly adequate therapy : in this investigation 64% of patients with elevated blood pressures after 6 months of therapy were found to be noncompliant.
It is not possible in our study to determine the effect of repeated questioning of the patient on the accuracy of the self-report or on the patient's compliance. Additional studies in this area would be of interest. Further exploration of quantitative rather than qualitative antihypertensive drug levels is also warranted in view of the excellent results reported for serum and salivary drug levels in both measuring and managing compliance for patients on phenytoin, 19 or theophylline. 20 We do not know how well our results can be applied to other populations. Since the results are derived from observations among a male, middle-aged, primarily blue collar working group, verification in other populations may be desirable before more general application. However, the compliance rates we observed were within the range cited in other studies. 1 Furthermore, we do feel that the results are reliable for at least the plant population from which participants were derived because a random selection process was used for screening and participation rates were acceptable (95% for screening; 94% for study entry of eligible subjects; and 96% for those on treatment at 6 months).
Maintenance of high compliance with prescribed therapy is essential if the benefits of therapy are to be realized. The management of compliance can be performed efficiently only if adequate methods of monitoring compliance are readily available. The methods described here are far from perfect but they can be applied in routine care and are a considerable improvement on the therapist's own estimate of compliance.
